Apexigen Completes $20 Million Series A Venture Round

Apexigen, a California antibody company with strong connections to several China pharmas, raised $20 million in Series A1 financing. Apexigen was originally formed to be the drug development arm of Epitomics, a company built around a rabbit-based platform for developing monoclonal antibodies. Two China companies – Simcere and 3SBio – have filed with the CFDA to begin clinical trials of Apexigen-discovered drugs. More details.... Stock Symbols: (NYSE: SCR) (NSDQ: SSRX) Share this with colleagues: // //